title: Effects of high-energy shock waves combined with biological response modifiers or Adriamycin on a human kidney cancer xenograft.
abstract: We have studied the effect of high-energy shock waves (HESW) alone or in combination with biological response modifiers (BRMs) or Adriamycin on the growth of the NU-1 human kidney cancer xenograft. When HESW are administered repeatedly (four sessions of 800 shock waves on days 0, 2, 4 and 6) a prolonged delay in tumor growth was found compared with that following a single administration. This effect was temporary, and several days after stopping the HESW administration the tumor regained its original growth potential (same doubling time). Tumor growth was suppressed for a longer period by the combination of 4 sessions of HESW and a single administration of Adriamycin, 5 mg/kg. Combination of HESW treatment with interferon alpha (5.0 ng/g body weight, three times/week) and tumor necrosis factor alpha (500 ng/g body weight, 5 days/week) s.c. around the tumor resulted in a complete cessation of tumor growth. While Adriamycin had an additive effect on HESW treatment, the combination with BRMs was highly synergistic.
authors.affiliation: Department of Urology, St. Radboud University Hospital, Nijmegen, The Netherlands.
authors.forename: G O
authors.initials: GO
authors.lastname: Oosterhof
authors.forename: G A
authors.initials: GA
authors.lastname: Smiths
authors.forename: J E
authors.initials: JE
authors.lastname: deRuyter
authors.forename: J A
authors.initials: JA
authors.lastname: Schalken
authors.forename: F M
authors.initials: FM
authors.lastname: Debruyne
mesh_terms: D000818:Animals; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D004317:Doxorubicin / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use; D014464:Ultrasonic Therapy
chemical_list: D007155:Immunologic Factors; D007370:Interferon Type I; D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin